‘Young blood’ plasma treatments unproven, possibly dangerous, says FDA

| | February 22, 2019
2-20-2019 c f b eb b e
Image credit: Joern Pollex
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Federal health regulators on [February 19] warned consumers against controversial “young blood” treatments — plasma infusions from young donors marketed for conditions such as Parkinson’s, Alzheimer’s, multiple sclerosis and post-traumatic stress disorder.

“There is no proven clinical benefit of infusion of plasma from young donors to cure, mitigate, treat, or prevent these conditions, and there are risks associated with the use of any plasma product,” [said FDA commissioner] Scott Gottlieb.

Plasma is the liquid portion of the blood and contains proteins that help blood to clot. It’s used to replace low levels of blood proteins in a range of medical situations. For example, some patients with liver disease are unable to make the proteins required for blood to clot.

Related article:  Viewpoint: Gene drive technology could eliminate malaria. But we must get it right, first

Clinics have been springing up that offer young-donor plasma infusions as a rejuvenating, “anti-aging” therapy. The FDA statement did not name any specific company; it was accompanied by a safety communication designed to inform consumers. But the agency warned it will consider taking enforcement action — such as sending warning letters demanding corrective actions — against companies that “abuse the trust of patients and endanger their health with uncontrolled manufacturing conditions.”

Read full, original post: FDA warns consumers against ‘young blood’ plasma infusions for dementia, PTSD and other conditions

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend